Table 4.

Details Of Head-To-Head Studies

First Author	Study	Year	Design	Groups	RA Duration	Quality Assessments			Months Follow-up	Treatments
						Allocation	Blinding	Bias Analysis		Non-Biologic	Biologic
Goekoop Ruitermann [45]	BeSt	2005	RCT	4	Early	Low risk	Low risk	Low risk	12	Combination DMARDs	Infliximab/DMARDs
Heimans [76]	Improved	2014	RCT	2	Early	Low risk	High risk	Unclear	12	Triple DMARDs	Adalimumab/MTX
Leirisalo-Repo [77]	Neo-Fin RA Co	2013	RCT	2	Early	Low risk	Low risk	Low risk	24	Triple DMARDs	Infliximab/Triple DMARDs
O’Dell [78]	Racat	2013	RCT	2	Est’lishd	Low risk	Low risk	Low risk	12	Triple DMARDs	Etanercept/MTX
Scott [79]	Tacit	2015	RCT	2	Est’lishd	Low risk	High risk	Indeterminate	12	Combination DMARDs	TNF inhibitors/DMARDs
Moreland [80]	Tear	2012	RCT	4	Early	Low risk	Low risk	Low risk	24	Triple DMARDs	Etanercept/MTX

Abbreviations: RCT Randomised controlled trial, Est’lishd Established, MTX Methotrexate, DMARD Disease modifying anti-rheumatic drugs, TNF Tumour necrosis factor